Skip to main content

Table 1 Characteristics of the BASE-II participants included in the present study

From: T cell phenotypes associated with insulin resistance: results from the Berlin Aging Study II

 

Men (n = 181)

Women (n = 256)

Age [years]

70 (67–73)

68 (66–70)

BMI [NR 18–25 kg/m2]

26.9 (25.0–29.0)

25.8 (23.4–28.6)

Body weight [kg]

82.1 (76.4–90.5)

68.0 (62.0–76.3)

Height [cm]

175.7 (171.0–180.0)

163.2 (158.9–168)

HbA1c [NR < 5.7%]

5.5 (5.2–5.7)

5.4 (5.2–5.7)

HOMA-IR (NR < 1.9)

2.0 (1.4–3.0)

1.7 (1.2–2.5)

ISIOGTT (NR > 4)a

5.6 (3.3–8.7)

5.7 (3.8–8.3)

Fasting PG (mg/dL)

102.5 (88.0–125.0)

104.0 (89.0–124.0)

PG in 75-g OGTT at 120 min (mg/dL)

94.0 (87.0–102.0)

89.0 (84.0–96.0)

Fasting Insulin in 75-g OGTT (mg/dL)

9.0 (6.3–12.3)

7.6 (5.7–10.4)

Insulin in 75-g OGTT at 120 min (mg/dL)

42.9 (25.6–72.4)

44.9 (29.7–67.3)

Triglycerides (NR </= 200 mg/dL)

104 (77–143)

91 (73–119)

HDL cholesterol (NR male/female =/>  35/45 mg/dL)

53 (45–65)

70 (57–79)

LDL cholesterol (NR < 130 mg/dL)

122 (100–147)

136 (112–162)

Cholesterol (NR < 200 mg/dL)

201 (177–228)

232 (202–256)

Obesity [n, %]

28 (15.5)

49 (19.1)

T2D [n, %]

20 (11.0)

17 (6.6)

HOMA-IR > 1.9 [n, %]

21 (12.1)

22 (9.1)

ISIOGTT < 4 [n, %]a

51 (31.8)

65 (28.6)

CRP (NR < 5 mg/L)

1.2 (0.7–2.3)

1.2 (0.6–2.0)

Basophils (NR 0–0.2 G/L)

0.05 (0.05–0.05)

0.05 (0.05–0.05)

Eosinophils (NR 0.02–0.5 G/L)

0.18 (0.11–0.24)

0.15 (0.10–0.220)

Leukocytes (NR 3.9–10.5 G/L)

5.7 (4.7–6.7)

5.5 (4.6–6.4)

Monocytes (NR 0.1–0.9 G/L)

0.45 (0.36–0.53)

0.35 (0.29–0.43)

Neutrophils (NR 1.5–7.7 G/L)

3.2 (2.7–4.0)

3.1 (2.5–3.7)

  1. Categorical data are presented as percentages. None of the continuous variables were normally distributed; thus, values are presented as median and interquartile range. BMI body mass index, HOMA-IR homeostasis model assessment of insulin resistance. ISIOGTT insulin sensitivity index, NR normal range, OGTT oral glucose tolerance test, PG plasma glucose, T2D type 2 diabetes. aISIOGTT was not assessed for participants with type 2 diabetes